| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 33.55 | 19.91 |
| Gross Profit | 20.64 | 11.90 |
| Pretax Income | -13.25 | -7.56 |
| Net Income | -13.34 | -8.00 |
| Diluted EPS | -0.19 | -0.69 |
- Net Income YoY
- -66.8%
Key highlights
- Quarterly revenue reached $33.55 million, a 68.5% increase from $19.91 million in the prior year
- Gross profit rose to $20.64 million compared to $11.90 million in Q3 2025
- Net loss for the quarter widened to $13.34 million from $8.00 million
- Full-year 2026 revenue guidance was raised to a range of $121 million to $123 million
- Diluted earnings per share improved to -$0.19 from -$0.69 in the comparable period
How the Period Went
Alamar Biosciences experienced substantial top-line expansion during the third quarter of 2026, with total revenue reaching $33.55 million, compared to $19.91 million in the same period last year. This 68.5% increase was accompanied by a corresponding rise in gross profit, which climbed from $11.90 million to $20.64 million. Despite the robust revenue growth, the company reported a widened net loss of $13.34 million, up from a loss of $8.00 million in Q3 2025. Diluted earnings per share improved to -$0.19 from -$0.69, primarily reflecting changes in the weighted-average shares outstanding as the company continues to scale its operations and capital structure.
Margins and Profitability
- Quarterly gross profit of $20.64 million reflects an approximate 61.5% gross margin on total revenue
- Pretax loss for the quarter widened to $13.25 million from $7.56 million in the prior year
- Net income declined 66.8% year-over-year as operating expenses for commercial scaling outpaced revenue gains
- Total nine-month revenue reached $89.0 million, more than double the $49.2 million reported in the first three quarters of 2025
- Cumulative nine-month net loss stands at $47.9 million, driven by aggressive investment in research and development
Business Overview
Alamar Biosciences operates in the high-growth proteomics sector, specializing in ultra-high sensitivity protein detection technologies essential for early disease research. The company’s flagship NULISA platform and ARGO HT System are designed to detect low-abundance biomarkers that are often invisible to traditional assays. Serving academic researchers and biopharmaceutical companies, Alamar focuses on critical therapeutic areas including oncology, neurology, and inflammatory diseases. The platform competes by offering high sensitivity paired with high multiplexing capabilities, enabling the identification of complex biological pathways in liquid biopsies. This technological positioning is central to the company's strategy of becoming a standard in clinical diagnostics and therapeutic development.
Financial Context
The Q3 2026 results extend a consistent sequential growth trend, following revenues of $26.0 million in the first quarter and $29.4 million in the second quarter, as reported in Alamar’s investor disclosures. Management recently raised its full-year 2026 revenue guidance to a range of $121 million to $123 million, according to GuruFocus. This upward revision reflects the increasing global adoption of the ARGO system. While the company remains in a capital-intensive loss-making phase, its revenue trajectory indicates a rapid scaling of its installed base and recurring consumable sales, which are fundamental to the long-term profitability of the life sciences tool business model.
Industry Landscape
- The proteomics market is transitioning toward high-throughput automated platforms to support large-scale population studies
- Competitors such as Quanterix and Olink are also intensifying focus on high-sensitivity assays for clinical diagnostics
- Alamar is currently supporting the 80,000-sample UK Biobank neurodegenerative disease study, expected to conclude by late 2027
- Management reaffirmed its target submission of the ARGO HT/DX clinical instrument to the FDA for marketing authorization by end of 2027
- Increasing demand for multi-omic data integration is driving new partnerships between proteomics and genomics providers
| Date | Announcement | Amount |
|---|---|---|
| 03 Nov 2026 | Full-year 2026 revenue guidance (raised)Source: gurufocus.com | – |
| 03 Nov 2026 | Q3 2026 revenueSource: investing.com | $33.5 Million |
| 10 Aug 2026 | Full-year 2026 revenue guidanceSource: investors.alamarbio.com | – |
| 10 Aug 2026 | Q2 2026 revenueSource: investors.alamarbio.com | $29.4 Million |
| 08 May 2026 | Q1 2026 revenueSource: investors.alamarbio.com | $26.0 Million |
SEC filing by Alamar Biosciences, Inc. announcing third quarter 2026 financial results.
Track Alamar Biosciences, Inc. live
Get the next Alamar Biosciences, Inc. SEC filing seconds after it lands.



